McDonald Elizabeth S, McCarthy Anne Marie, Akhtar Amana L, Synnestvedt Marie B, Schnall Mitchell, Conant Emily F
1 Breast Imaging Division, Department of Radiology, University of Pennsylvania, Perelman School of Medicine, 3400 Spruce St, 1 Silverstein, Philadelphia, PA 19104-4283.
2 General Medicine Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
AJR Am J Roentgenol. 2015 Nov;205(5):1143-8. doi: 10.2214/AJR.15.14406.
Baseline mammography studies have significantly higher recall rates than mammography studies with available comparison examinations. Digital breast tomosynthesis reduces recalls when compared with digital mammographic screening alone, but many sites operate in a hybrid environment. To maximize the effect of screening digital breast tomosynthesis with limited resources, choosing which patient populations will benefit most is critical. This study evaluates digital breast tomosynthesis in the baseline screening population.
Outcomes were compared for 10,728 women who underwent digital mammography screening, including 1204 (11.2%) baseline studies, and 15,571 women who underwent digital breast tomosynthesis screening, including 1859 (11.9%) baseline studies. Recall rates, cancer detection rates, and positive predictive values were calculated. Logistic regression estimated the odds ratios of recall for digital mammography versus digital breast tomosynthesis for patients undergoing baseline screening and previously screened patients, adjusted for age, race, and breast density.
In the baseline subgroup, recall rates for digital mammography and digital breast tomosynthesis screening were 20.5% and 16.0%, respectively (p = 0.002); digital breast tomosynthesis screening in the baseline subgroup resulted in a 22% reduction in recall compared with digital mammography, or 45 fewer patients recalled per 1000 patients screened. Digital breast tomosynthesis screening in the previously screened patients resulted in recall reduction of 14.3% (p < 0.001; p for interaction = 0.21). The recall rate reduction for baseline screening was especially pronounced in women younger than 50 years (p = 0.005). DBT implementation resulted in an increase in cancer detection in the baseline subgroup of 40.5% versus an increase in the previously screened subgroup of 17.4%. DBT implementation resulted in an increase in PPV1 in the baseline subgroup of 85% versus 35.3% in the previously screened subgroup, although the p-interaction was not significant.
If resources are limited, women younger than 50 years who are undergoing baseline screening or do not have prior available mammograms may benefit more from digital breast tomosynthesis than from digital mammography alone.
基线乳腺钼靶检查的召回率显著高于有可对比检查的乳腺钼靶检查。与单纯数字乳腺钼靶筛查相比,数字乳腺断层合成可降低召回率,但许多机构采用的是混合模式。为了在资源有限的情况下最大化数字乳腺断层合成筛查的效果,选择哪些患者群体受益最大至关重要。本研究评估了基线筛查人群中的数字乳腺断层合成。
比较了10728例接受数字乳腺钼靶筛查的女性(包括1204例[11.2%]基线检查)和15571例接受数字乳腺断层合成筛查的女性(包括1859例[11.9%]基线检查)的结果。计算召回率、癌症检出率和阳性预测值。逻辑回归估计了接受基线筛查的患者以及既往已筛查患者中数字乳腺钼靶与数字乳腺断层合成的召回比值比,并根据年龄、种族和乳腺密度进行了调整。
在基线亚组中,数字乳腺钼靶筛查和数字乳腺断层合成筛查的召回率分别为20.5%和16.0%(p = 0.002);与数字乳腺钼靶相比,基线亚组中的数字乳腺断层合成筛查使召回率降低了22%,即每1000例筛查患者中少召回45例患者。既往已筛查患者中的数字乳腺断层合成筛查使召回率降低了14.3%(p < 0.001;交互作用p = 0.21)。基线筛查的召回率降低在50岁以下女性中尤为明显(p = 0.005)。实施数字乳腺断层合成使基线亚组的癌症检出率提高了40.5%,而既往已筛查亚组提高了17.4%。实施数字乳腺断层合成使基线亚组的PPV1提高了85%,而既往已筛查亚组提高了35.3%,尽管交互作用p值不显著。
如果资源有限,正在接受基线筛查或既往没有乳腺钼靶检查的50岁以下女性可能从数字乳腺断层合成中比单纯从数字乳腺钼靶中获益更多。